Sales figures for rosacea prescription products are generally hard to come by. This is about as public as they get – the owners of Galderma, Nestle are touting how well Soolantra sales growth is contributing to their profits.
In Nestlé skin health, we have a consumer range, which is growing north of — which is growing double digit, north of 10%.
And we brought in the market some breakthrough innovation with Soolantra, which is a new topical treatment for rosacea, which grew by 36%. So, all of these examples show you what we can deliver in terms of innovation and contribute to growth.
Nestle Skin Health was the company created in 2014 to house Galderma and other R&D and consumer skincare lines.
Soolantra is a hit
So Soolantra is being well accepted by rosacea sufferers and is selling well. It does seem that Soolantra has been generally well tolerated and beneficial to rosacea sufferers who have posted Soolantra reviews online.
I suspect that the consumer range alluded to within Nestle Skin Health, that is growing sales faster than 10% is in fact Cetaphil, another Galderma product that is generally well liked by rosacea sufferers.
- Soolantra more expensive than Finacea, but better, apparently
- Soolantra listed at $275 a tube
- Australia has the cheapest rosacea treatments in the world!
- Soolantra better than Metrogel at long term remission
- Soolantra User Reviews
- How much do Rosacea Prescriptions Really Cost?
- Oracea and Finacea prescription prices are increasing !